Prevalence of diabetic macular edema among type II diabetic patients in tele-screening program using OCT and fundus photos in a tertiary hospital, Riyadh, Saudi Arabia

沙特阿拉伯利雅得一家三级医院利用光学相干断层扫描和眼底照片开展远程筛查项目,调查II型糖尿病患者中糖尿病性黄斑水肿的患病率

阅读:1

Abstract

PURPOSE: To provide local data on the prevalence and risk factors of diabetic macular edema in the Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. METHOD: A cross-sectional cohort study was conducted to screen the prevalence of diabetic macular edema among diabetic patients, with 906 patients randomly selected between May 2023 and September 2023 in a tele-screening program using OCT and fundus photos at the Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. RESULTS: In a sample of 906 diabetic patients who participated in a tele-screening program, 38 cases of diabetic macular edema (DME) were diagnosed, resulting in a prevalence of 4.19%. Males and females each composed 50% of the sample. The average age was 61.39 years (SD = 10.114), and 31.6% had diabetes for over 15 years. Most patients had comorbidities, including hypertension (86.8%) and dyslipidemia (89.5%). Diabetic complications were common: neuropathy was present in 23.6%, and nephropathy was present in 21%. Among the 48 eyes assessed, the mean central macular thickness was 315 ± 69 μm. The distribution of diabetic retinopathy severity in 48 eyes included 17 (35%) no retinopathy, 8 (17%) mild NPDR, 15 (31%) moderate NPDR, 7 (15%) severe NPDR, and 1 (2%) PDR. Center-involved DME was found in 45.8% of the eyes, whereas non-center-involved DME was observed in 54.2% of the eyes. CONCLUSION: This study in Riyadh, Saudi Arabia, revealed a 4.19% prevalence of diabetic macular edema (DME), emphasizing the importance of regular screening, especially for patients with longstanding diabetes, hypertension, and dyslipidemia.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。